ANTISECRETORY EFFECTS AND PHARMACOKINETICS OF LOW-DOSE RANITIDINE

被引:0
|
作者
KOSS, MA
HOGAN, DL
LANE, J
STEINBACH, JH
ISENBERG, JI
机构
[1] UNIV CALIF SAN DIEGO,MED CTR,DIV GASTROENTEROL 8413,SAN DIEGO,CA 92103
[2] UNIV CALIF SAN DIEGO,PHARM SERV,SAN DIEGO,CA 92103
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The purpose of this study was to examine the anti-secretory effect of low doses of orally administered ranitidine on meal-stimulated gastric acid secretion and assess its pharmacokinetics. The effect of 20, 40, 60 and 80 mg of ranitidine p.o. and placebo were tested on 5 separate days (Latin square, double-blind) in 15 healthy males (mean age 35 years). Gastric acid secretion was measured prior to and for 8 h following two sequential mixed liquid meals administered at 4-h intervals. Venous blood samples were obtained at frequent intervals before and following each dose for determination of plasma ranitidine concentration by high pressure liquid chromatography. Each dose of ranitidine significantly (P < 0.01) decreased the peak and cumulative 4-h acid secretory responses to the first meal (range 58-93%), and the 60 and 80 mg doses significantly inhibited the response to the second meal by 31 and 43%, respectively. Total 8-h meal-stimulated acid outputs were decreased significantly in a dose-related manner (range 38-73%). Peak plasma ranitidine occurred approximately 1 h after dosing. Ranitidine t(max), t1/2 and clearances were independent of dose, however, AUC and C(max) were dose-related. Inhibition of acid secretion was related to plasma ranitidine concentration; the mean IC50 was 27 (+/- 6.4) ng/ml. We conclude that modest doses (equivalent to 7-27% of the daily therapeutic dose) of ranitidine effectively suppress meal-stimulated gastric acid secretion in a dose-related manner. If these doses are of clinical efficacy, it may be possible for substantial cost savings to occur.
引用
收藏
页码:417 / 422
页数:6
相关论文
共 50 条
  • [41] Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis
    Chladek, J
    Grim, J
    Martinkova, J
    Simkova, M
    Vaneckova, J
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2005, 96 (03) : 247 - 248
  • [42] Pharmacokinetics of indinavir in a BID regimen with or without low-dose ritonavir
    Burger, DM
    Hugen, PWH
    Prins, J
    Reiss, P
    Lange, JMA
    AIDS, 1998, 12 : S10 - S10
  • [43] PHARMACOKINETICS IN LOW-DOSE EXTRAPOLATION USING ANIMAL CANCER DATA
    WHITTEMORE, AS
    GROSSER, SC
    SILVERS, A
    FUNDAMENTAL AND APPLIED TOXICOLOGY, 1986, 7 (02): : 183 - 190
  • [44] Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis: Therapeutic implications
    Bannwarth, B
    Pehourcq, F
    Lequen, L
    THERAPIE, 1997, 52 (02): : 129 - 132
  • [45] PHARMACOKINETICS OF LOW-DOSE METHOTREXATE IN RHEUMATOID-ARTHRITIS PATIENTS
    HERMAN, RA
    VENGPEDERSEN, P
    HOFFMAN, J
    KOEHNKE, R
    FURST, DE
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (02) : 165 - 171
  • [46] Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors
    Hempel, G
    Rübe, C
    Mosler, C
    Wienstroer, M
    Wagner-Bohn, A
    Schuck, A
    Willich, N
    Boos, J
    ANTI-CANCER DRUGS, 2003, 14 (06) : 417 - 422
  • [47] THE PHARMACOKINETICS OF LOW-DOSE BENZO(A) PYRENE IN 2 STRAINS OF MICE
    ZANE, PA
    FLYNN, EJ
    FEDERATION PROCEEDINGS, 1986, 45 (03) : 206 - 206
  • [48] Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis
    Bannwarth, B
    Pehourcq, F
    Schaeverbeke, T
    Dehais, J
    CLINICAL PHARMACOKINETICS, 1996, 30 (03) : 194 - 210
  • [49] THE PHARMACOKINETICS OF LOW-DOSE DEXAMETHASONE IN CONGENITAL ADRENAL-HYPERPLASIA
    YOUNG, MC
    COOK, N
    READ, GF
    HUGHES, IA
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 37 (01) : 75 - 77
  • [50] Pharmacokinetics and efficacy of low-dose ketoprofen in postoperative dental pain
    Seymour, RA
    Kelly, PJ
    Hawkesford, JE
    CLINICAL DRUG INVESTIGATION, 1998, 15 (04) : 279 - 284